Edgewise Therapeutics Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics targeting serious muscle diseases. The company generates no product revenue as of the 10-K filed 2026-02-26, operating entirely on capital raised through equity financings to fund research and clinical development. Its lead product candidate, sevasemten, holds Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, and the company is advancing additional candidates including EDG-series compounds. Edgewise is focused on rare and serious muscle-related indications, with regulatory filings and approvals pursued across the United States and Europe. The company has no disclosed commercial partnerships generating revenue in the filing excerpts available.

Revenue model

Pre-revenue clinical-stage company. No product sales or licensing revenue disclosed in the 10-K filed 2026-02-26. Operations are funded through capital raises.

Products and services

Sevasemten: lead product candidate with Orphan Drug Designation and Rare Pediatric Disease Designation. Additional pipeline candidates referenced as EDG-series compounds. All candidates are in clinical or preclinical development as of the 10-K filed 2026-02-26.

Customers and end markets

Target patient populations in rare and serious muscle diseases. No commercial customers as of the 10-K filed 2026-02-26. End markets include rare pediatric and orphan disease indications.

Value-chain role

Drug developer. Clinical-stage, pre-commercialization. Conducts clinical trials and pursues regulatory approvals in the US and Europe.

Geographic exposure

United States primary. Regulatory activities also referenced in Europe and other jurisdictions, per the 10-K filed 2026-02-26.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: ANI Pharmaceuticals Inc Atea Pharmaceuticals Inc Tvardi Therapeutics Inc Collegium Pharmaceutical Inc Evolus Inc Johnson & Johnson Nuvation Bio Inc Phibro Animal Health Corp Tricida, Inc.